source
- Roche's Genentech reports 43% reduction in kidney damage marker in phase 3 IgA nephropathy trialRoche Genentech disclosed detailed results from its phase 3 IMAgINATION trial of the antisense oligonucleotide sefaxersen in patients with IgA nephropathy. The trial showed a 43.1% greater reducti…
- Takeda’s ADC arcotatug tavatecan shows survival benefit in phase 3 gastric cancer trialTakeda, together with Innovent Biologics, presented results from a late‑stage study of its next‑generation claudin‑18.2 antibody‑drug conjugate, arcotatug tavatecan (also known as IBI343 or TAK‑921…